Nirogi, Ramakrishna http://orcid.org/0000-0002-2045-0784
Benade, Vijay
Goyal, Vinod Kumar
Pandey, Santosh Kumar
Mohammed, Abdul Rasheed
Shinde, Anil
Dogiparti, Dhanunjay
Ravula, Jyothsna
Jetta, Satish
Palacharla, Veera Raghava Chowdary
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
https://doi.org/10.1007/s40261-022-01189-9
Documents that mention this clinical trial
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
https://doi.org/10.1007/s40261-022-01189-9
Article History
Accepted: 1 August 2022
First Online: 13 August 2022
Declarations
:
: This study was sponsored by Suven Life Sciences Ltd.
: R. Nirogi, V. Benade, V.K. Goyal, S.K. Pandey, A.R. Mohammed, A. Shinde, D. Dogiparti, J. Ravula, S. Jetta, and V.R.C. Palacharla are employees of Suven Life Sciences Ltd.
: The study was conducted in compliance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice Guidelines, and the Declaration of Helsinki. The protocols were reviewed and approved by the institutional review board. The study was conducted at IQVIA Phase One Services, Overland Park, KS, USA.
: All subjects provided written informed consent.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors were involved in the study design and the discussion and interpretation of the results. All authors repeatedly edited the manuscript and approved the final version.